Aim: To evaluate the utility of intimal thickness and interstitial width as a primary efficacy
variable in the design of clinical trials aimed to modify the natural history of chronic allograft
nephropathy. Methods: A donor and a 4-month protocol biopsy were evaluated in 40 stable
grafts according to the Banff schema. In 27 patients, a second protocol biopsy was done at 1
yr. Arterial intimal volume fraction (Vvintima/artery) and cortical interstitial volume fraction
(Vvinterstitium/cortex) were estimated with a point counting technique. Results: Chronic …